X0202 SCHEDULE 13D/A 0001104659-21-112194 0000042872 XXXXXXXX LIVE 008 Common Stock, par value $0.0001 per share 04/24/2026 false 0001818382 020751103 HUMACYTE, INC.

2525 East North Carolina Highway 54 Durham NC 27713

Robert A. Grauman 646 202-2932 145 West 86 Street New York NY 10024 Thomas D. Brouillard 781 699 9000 Fresenius Medical Care Holdings, Inc. 920 Winter Street Waltham MA 02451-1547 Christof Koester 011 49 6172 609 0 Fresenius Medical Care AG Else-Kroener Strasse 1 Bad Homburg 2M 61352 0000042872 N Fresenius Medical Care Holdings, Inc. WC N NY 0.00 18312735.00 0.00 18312735.00 18312735.00 N 8.4 CO 0001333141 N Fresenius Medical Care AG AF N 2M 0.00 18312735.00 0.00 18312735.00 18312735.00 N 8.4 CO Common Stock, par value $0.0001 per share HUMACYTE, INC. 2525 East North Carolina Highway 54 Durham NC 27713 This Amendment No. 8 amends certain information contained in the Schedule 13D originally filed by Fresenius Medical Care Holdings, Inc., a New York Corporation ("FMCH") and Fresenius Medical Care AG a German stock corporation ("FME AG") on September 2, 2021, as previously amended by Amendment No. 1 filed December 1, 2023, Amendment No. 2 filed March 7, 2024, Amendment No 3 filed November 18, 2024, Amendment No 4 filed May 22, 2025, Amendment No 5 filed solely by FME AG on October 16 2025, Amendment No. 6 filed by FME AG and FMCH on January 9;2026 and Amendment No. 7 filed March 24, 2026 (as so amended, the "Schedule 13D"), with respect to the common stock, par value $0.0001 per share (the "Common Stock") of Humacyte, Inc., a Delaware corporation, formerly known as Alpha Healthcare Acquisition Corp. (the "Issuer" or "Humacyte"). Capitalized terms not otherwise defined herein have the meanings set forth in the Schedule 13D. Except as provided herein, this Amendment No. 8 does not modify any of the information previously reported on the Schedule 13D. The description of the Distribution Agreement in Item No. 4 of the Schedule 13D is hereby amended and superseded by the addition of the following information: On April 21, 2026, FMCH and Humacyte entered into a Third Amendment to the 2018 Distribution Agreement between FMCH and Humacyte. As amended, the distribution agreement now provides that Humacyte will have the exclusive rights to distribute Symvess(R) (acellular tissue engineered vessel) outside the U.S. and in the rest of the world, and FMCH will be entitled to low-single-digit royalties on net sales of Symvess(R) outside the U.S. Existing terms related to the U.S. remain unchanged. FMCH agreed to reversion of ex-U.S. distribution rights to Humacyte as part of FME AG's "Legacy Portfolio Optimization program," as described in FME AG's public filings. The foregoing description of the Third Amendment to the Distribution Agreements does not purport to be complete and is qualified in its entirety by the terms and conditions of such Amendment, which is an exhibit to this Schedule 13D Amendment No. 8). Exhibit 99.7. Third Amendment dated April 21, 2026 to Distribution Agreement dated June 25, 2018 between Fresenius Medical Care Holdings, Inc. and Humacyte, Inc. (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Humacyte, Inc. on April 24, 2026)*. * The Issuer states in the Form 8-K that certain confidential information contained in this exhibit, market by brackets, has been omitted because the information (i) is not material and (ii) is the type of information the Issuer both customarily and actually treats as private or confidential. Fresenius Medical Care Holdings, Inc. /s/ Bryan Mello 04/24/2026 Fresenius Medical Care AG /s/ ppa Dr. Angela Koelbl 04/24/2026 /s/ ppa Christof Koester 04/24/2026